



edap tms
Bringing New Horizons to Therapy

EDAP TMS SA : EDAP to Showcase Suite of Therapeutic Ultrasound Products During the American Urology Association Annual Meeting

April 29, 2019

EDAP to Provide Live Demonstrations and Host Q&A with Interested Parties at Booth #2211

LYON, France, April 29, 2019 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate the capabilities of its range of minimally-invasive therapeutic ultrasound products, including its breakthrough Focal One® HIFU (High Intensity Focused Ultrasound) advanced robotic technology for the targeted ablation of prostate tissue, at booth #2211 at the [American Urology Association \("AUA"\) Annual Meeting](#), which is being held May 3-6, 2019, at Mc Cornick Place, in Chicago, IL. This will be the first time that EDAP is showcasing Focal One at AUA.

This year's conference will also feature several key presentations and scientific communications on focal therapy and Focal One. Among the presentations, Dr. Eduard Baco of Oslo University Hospital in Norway is scheduled to discuss his progress in a randomized clinical trial evaluating Focal One versus robotic prostatectomy.

Focal One HIFU makes it possible for doctors to deliver a non-invasive precision treatment to destroy targeted tissue in the prostate while leaving healthy tissue intact. This reduces the likelihood of negative side effects commonly related to prostate surgery like incontinence and impotence. The Focal One prostate tissue ablation system received 510(k) clearance from the FDA in June 2018, and has already been sold in five major teaching institutions around the US.

About AUA 2019

For more than a century, the American Urological Association has stood at the forefront of developing innovative, evidence-based urologic education for urologists and urologic health care professionals worldwide. AUA2019 continues this longstanding tradition, assembling thought leaders from around the world to provide you with the very latest advancements in urologic medicine. Last year's Annual Meeting welcomed more than 16,000 attendees from more than 100 countries around the globe, underscoring the meeting's value to the global urologic community. The 2019 meeting will feature more innovative programming and educational offerings than ever before, providing unparalleled access to groundbreaking research, the latest clinical guidelines, a wide array of courses and forums, and the very latest technologies in urology.

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit <http://www.edap-tms.com>, and us.hifu-prostate.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Company Contact

Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact

Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com



edap tms
Bringing New Horizons to Therapy